InflaRx N.V. (Nasdaq: IFRX) will deliver a late‑breaking oral presentation of its Phase 3 vilobelimab data for pyoderma gangrenosum (PG) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The presentation is scheduled for March 28, 2026 at 2:24 p.m. MT and will be delivered by Dr. Benjamin Kaffenberger, MD.
The data come from a multicenter, randomized, placebo‑controlled Phase 3 trial that evaluated vilobelimab—an intravenous anti‑C5a monoclonal antibody—in patients with ulcerative PG. The trial was terminated for futility in May 2025, but post‑hoc analyses have revealed signals of efficacy, prompting InflaRx to share detailed results with the dermatology community.
InflaRx’s announcement underscores its ongoing effort to expand the clinical portfolio of its complement‑targeting platform beyond hidradenitis suppurativa and chronic spontaneous urticaria. The company is also prioritizing its oral C5aR inhibitor, INF904 (izicopan), for other inflammatory diseases, reflecting a strategic pivot after the PG trial outcome.
The presentation is part of the Late‑Breaking Research abstract session and will provide the first in‑depth look at vilobelimab’s efficacy and safety profile in PG. Dr. Camilla Chong, Chief Medical Officer, said, "It is an honor that our Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG) have been selected for a late‑breaking oral presentation at AAD. We look forward to engaging with the dermatology community on these critical findings in PG and our development program targeting the role of C5a/C5aR inhibition in other chronic immuno‑inflammatory diseases."
InflaRx will report its Q4 2025 results on March 19, 2026, and the company has received a Nasdaq deficiency notice for maintaining a bid price below $1.00 for 30 consecutive trading days. The upcoming presentation and earnings release will be closely watched for indications of how the company’s clinical and financial trajectory may evolve.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.